Poolbeg Pharma plc

A reminder that our Principal Scientist Liam Tremble will be attending the International Myeloma Society’s 22nd Annual Meeting & Exposition in Toronto, Canada. This event will provide focus on both the basic, preclinical, and clinical aspects of Myeloma. Meet with Liam to learn more about POLB 001, our p38 MAP Kinase inhibitor being developed for the prevention of Cytokine Release Syndrome (CRS) associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. Learn more: https://lnkd.in/gu46Nbdn #POLB #Myeloma #AnnualMeeting #Toronto #Immunotherapy #Cancer

Our Chief Executive Officer Jeremy Skillington, PhD will be participating in a panel discussion at the Optimum Strategic Communications 17th Annual Healthcare Investor Conference on Thursday 9 October. 📍The King’s Fund, London ⌚14:15 🗣️ Panel: Thriving in the tough times: scaling smart and staying strong Jeremy will take to the stage alongside Nicole Mather of IBM Consulting and Nicholas Keher, CFO at Oxford Nanopore. The session will be chaired by Kristin-Anne Rutter, Executive Director at Cambridge University Health Partners. Register to attend: https://lnkd.in/gxNifZFN #POLB #Conference #Investors #Healthcare #LifeScience #Pharma #London #Optimum

Tune in Deep Tech Digest Base to Base Biotech podcast with Jim Cornall who speaks to Chief Executive Officer Jeremy Skillington, PhD on Poolbeg Pharma’s exciting pipeline.   👉Company overview & history ✅POLB 001 addressing cancer immunotherapy-induced CRS 🔍About Cytokine Release Syndrome 🔬Upcoming Phase 2a trial 🚀Developing an oral, patient-friendly obesity treatment 🧑🔬Upcoming Proof of Concept Trial   Listen here from 37:26: https://lnkd.in/eKp9FDym   #POLB #Podcast #Biotech #CRS #Oncology #GLP1 #Pharma

During our panel discussion at the Investor Summit our CEO Jeremy Skillington, PhD discussed the benefits of Orphan Drug Designation (ODD) and how this award from the FDA significantly benefits POLB 001’s development. 👉7-year U.S. market exclusivity 💪Tax benefits for clinical trials ✅Potential waiver exemption of Prescription Drug User Fee Act application fees 📞Direct line to FDA around clinical trials Learn more about our ODD announcement for POLB 001 here: https://lnkd.in/eMr5S5gX #POLB #ODD #FDA #ScientificResearch #MarketExclusivity #ClinicalTrials #CRS #Immunotherapy #Cancer #Oncology

September is Blood Cancer Awareness Month, a time to shine a light on a group of cancers which despite the fact they might not be visible on the surface, are equally as life-threatening. Blood cancer includes over 100 different types including the likes of leukaemia, lymphoma, myeloma and affects thousands of people across the globe. Blood cancer is the fifth most common and the third biggest cancer killer in the UK. Symptoms are often invisible, with it often being referred to as the “hidden cancer”. Swipe along to learn more about blood cancer & share our post to raise awareness. Share, support and advocate. Awareness can save lives. Learn more:  https://lnkd.in/eAMmu3E #POLB #BloodCancer #Awareness #Blood #Cancer #Oncology #Leukaemia  #Myeloma

Our CEO highlights how many treatments are available for the treatment of CRS and how POLB 001 compares as a preventative therapy.    👉 “Surprisingly very few” treatments available 🏥 Preventing CRS has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals - reaching more patients  🚀 "Remove CRS and there could be a greater market" for cancer immunotherapies - Pharma keen to drive revenue of existing drugs    Watch the full recording available here: https://lnkd.in/gAYEyv2z #POLB #InvestorSummit #CRS #Immunotherapy #ScientificResearch #Oncology

Our Executive Chair Cathal Friel took part in a panel discussion on 'De-equitisation of Global Markets' at the Investor Summit. He was joined by  fellow panellists — Mark Wharrier, Joe Winkley, Sarah Content CFA — and moderated David Belle. The session explored global trends, the future of UK markets, the impact of geopolitics, and the political pressures shaping the UK. Cathal emphasised his positive outlook on AIM, which he believes remains a vital platform for innovation and growth. Watch the full recording here: https://lnkd.in/eyRDGnZt #InvestorSummit #POLB #Markets #AIM

Tune into our snippet from CEO Jeremy Skillington, PhD, who provides a timeline for POLB 001’s upcoming milestones ✅Trial to commence before the end 2025 ☑️Interim data in H1 2026 🚀Trial completion by H2 2026 🤝Take datasets, intellectual property to partnering with Big Pharma ➡️ODD accelerates progression into the clinic 👉Potential to go to a straight into a Phase 3 Learn more about POLB 001, a Preventative Therapy Targeting Cancer Immunotherapy-Induced CRS: https://lnkd.in/eGgQBKFA #POLB #InvestorSummit #CRS #Immunotherapy #Treatments #ScientificResearch #Oncology #CytokineReleaseSyndrome #Inflammation

“CRS is a big problem” Dr Martin Kaiser, Consultant Haemato-Oncologist The Institute of Cancer Research & Royal Marsden Hospital discusses Cytokine Release Syndrome (CRS) and its impact on cancer immunotherapy administration. Treatment is limited to specialist cancer clinics due to the risk of CRS, some treatment centres in the US require proof via an application that they can deal with CRS.     Newer cancer immunotherapy treatments have the potential to have “higher CRS rates than we have at the moment”.   “We need new solutions”     A treatment, such as POLB 001 has the potential to enable cancer immunotherapy treatment to be administered in a community setting, closer to patients' homes.     If you missed the panel discussion, you can watch it here: https://lnkd.in/gAYEyv2z #POLB #InvestorSummit #CRS #Immunotherapy #Treatments #ScientificResearch #Oncology #Cancer #CytokineReleaseSyndrome

Our Principal Scientist Liam Tremble will be attending the International Myeloma Society’s 22nd Annual Meeting & Exposition on 17 September in Toronto, Canada. This event will provide focus on both the basic, preclinical, and clinical aspects of Myeloma. Meet with Liam to learn more about POLB 001, our p38 MAP Kinase inhibitor being developed for the prevention of Cytokine Release Syndrome (CRS) associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. Learn more: https://lnkd.in/gu46Nbdn #POLB #Myeloma #AnnualMeeting #Toronto #Immunotherapy #Cancer